Peptide ScheduleCJC-1295 + Ipamorelin
Benefits
About CJC-1295 + Ipamorelin
This pre-mixed blend combines CJC-1295 (No DAC) and Ipamorelin in equal parts — the most popular growth hormone stack in the peptide world. The GHRH (CJC) and GHRP (Ipamorelin) work in tandem: CJC-1295 amplifies the GH pulse while Ipamorelin triggers it. Together they produce a powerful, clean GH release without cortisol, prolactin, or hunger spikes.
Who Should Consider CJC-1295 + Ipamorelin
- Adults over 30 seeking anti-aging and recovery benefits
- Athletes and bodybuilders optimizing body composition and recovery
- Adults with age-related GH decline (somatopause)
- Individuals with poor sleep quality seeking deeper restorative sleep
- Post-injury patients wanting accelerated tissue repair
How CJC-1295 + Ipamorelin Works
CJC-1295 (No DAC) is a modified growth hormone-releasing hormone (GHRH) analog that binds the GHRH receptor (GHRHR) on anterior pituitary somatotroph cells, activating Gs-coupled adenylyl cyclase and raising intracellular cAMP. This primes the somatotroph for GH synthesis and release. Ipamorelin is a pentapeptide ghrelin mimetic that binds the growth hormone secretagogue receptor (GHS-R1a), activating Gq/11 signaling, raising intracellular calcium via IP3, and directly triggering GH exocytosis. When both pathways are activated simultaneously, the GH pulse is amplified beyond what either agent produces alone — GHRH sets the amplitude of the pulse while the ghrelin mimetic sets the timing. Ipamorelin is notable for its selectivity: unlike GHRP-2 and GHRP-6, it does not significantly elevate cortisol, prolactin, or ACTH at therapeutic doses, producing a cleaner hormonal profile. The combined GH release follows the natural pulsatile pattern rather than creating a sustained supraphysiological plateau, which preserves negative feedback regulation. Downstream, the elevated GH pulse stimulates hepatic IGF-1 production, promoting anabolic effects in muscle, bone, and connective tissue while enhancing lipolysis through hormone-sensitive lipase activation in adipocytes.
What to Expect
Improved sleep quality and deeper REM cycles. Mild water retention possible as GH levels rise.
Faster recovery from training. Skin and hair quality begin to improve. Increased energy and mood stability.
Noticeable body composition changes — reduced abdominal fat, improved muscle tone. Joint and connective tissue recovery.
Full anti-aging benefits emerge — improved skin elasticity, sustained fat loss, enhanced exercise capacity.
Benefits plateau. Cycle off for 4 weeks to maintain receptor sensitivity before restarting.
Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 200mcg | Daily |
| Moderate | 300mcg | Daily |
| Aggressive | 400mcg | 2x Daily |
Note: Pre-mixed GH stack (5mg CJC + 5mg Ipamorelin). Most popular combo for clean GH release. Dose is total mcg from vial. Take on empty stomach, before bed or post-training.
How to Inject CJC-1295 + Ipamorelin
Reconstitute the pre-mixed 10mg vial (5mg CJC-1295 + 5mg Ipamorelin) with 2mL bacteriostatic water. This yields a concentration of 5,000 mcg/mL total peptide. Inject subcutaneously using an insulin syringe (29-31 gauge). Preferred injection sites: lower abdomen (2 inches from navel) or upper thigh. Inject on an empty stomach — ideally 2+ hours after your last meal. The most common timing is 30 minutes before bed to amplify the natural nocturnal GH pulse. A second dose can be taken post-workout on training days. Rotate injection sites to avoid lipodystrophy. Store the reconstituted vial refrigerated at 2-8°C.
Cycling Protocol
Standard protocol is 12-16 weeks on, followed by 4 weeks off to maintain GHS-R1a receptor sensitivity. Some users run 5 days on / 2 days off within each cycle week. Dose before bed on an empty stomach (at least 2 hours fasted) to align with natural nocturnal GH pulsatility. Avoid eating for 30 minutes post-injection to prevent insulin-mediated blunting of GH release.
Pharmacokinetics
Source: Ipamorelin t½ ~2h drives dosing frequency (Johansen et al. 1999 PMID 10496658); CJC-1295 No DAC t½ ~30 min
Pharmacokinetics — Active Dose Over Time
t½ = ~30 minDisclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
Side Effects
Facial flushing, mild headache, tingling. Generally very well-tolerated. Best on empty stomach.
Contraindications
- Active cancer or history of malignancy — GH promotes cell proliferation
- Diabetes mellitus — GH antagonizes insulin and may worsen glycemic control
- Pregnancy or breastfeeding
- Active pituitary tumors or other intracranial neoplasms
- Hypersensitivity to GHRH analogs or ghrelin mimetics
Drug Interactions
- Insulin and oral hypoglycemics — GH release antagonizes insulin action; blood glucose monitoring required
- Corticosteroids — may blunt GH response and counteract benefits; chronic use reduces efficacy
- Other GH secretagogues (GHRP-2, GHRP-6, sermorelin) — additive GH release increases side effect risk; avoid stacking without medical supervision
- Thyroid hormones — GH can accelerate T4-to-T3 conversion; monitor thyroid function
- CYP450-metabolized drugs — GH may alter hepatic clearance of drugs metabolized by CYP3A4
Storage & Stability
Related Peptides
References
- Prolonged Stimulation of GH and IGF-I Secretion by CJC-1295 in Healthy AdultsPubMed 16352683
- Ipamorelin, the First Selective Growth Hormone SecretagoguePubMed 9849822
- Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin in Human VolunteersPubMed 10496658
- Pharmacokinetic Evaluation of Ipamorelin and Other Peptidyl GH SecretagoguesPubMed 9879640